Anygen Co., Ltd. (196300)

Overview

Anygen Co., Ltd., founded in 2000 and based in Gwangju-si, South Korea, operates as a bio-venture company specializing in the manufacture and international sale of peptide biomaterials and pharmaceutical raw materials. The company has carved a niche in the development of peptides for various applications, including those geared towards therapeutic uses. It is actively engaged in the research and development of promising anti-cancer therapies and treatments for other severe conditions such as viral infections, multidrug-resistant bacterial infections, diabetes, obesity, and ulcerative colitis. Leveraging its proficiency in peptide technology, Anygen aims at advancing healthcare solutions through innovation and quality-driven research.

Products and Services

• GMP, Generic, Custom, and Catalog Peptides

  Anygen produces a wide range of peptide biomaterials suitable for diverse applications, including drug development and research. These peptides are tailored to meet the specific requirements of their clients, ensuring high quality and precision.

• AGM-331

  Targeted for anti-cancer therapy, AGM-331 is currently in the pre-clinical development phase. This promising compound is part of Anygen's efforts to innovate in the field of oncology.

• AGM-130

  Indicated for the treatment of triple-negative breast cancer, AGM-130 is under Phase I development. It represents Anygen's commitment to addressing hard-to-treat cancers.

• AGM-380

  Currently in the pre-clinical development phase, AGM-380 is aimed at treating viral infections. This development showcases Anygen's dedication to combating infectious diseases with novel solutions.

• AGM-290

  This compound is focused on treating infections caused by multidrug-resistant bacteria and is in the pre-clinical development phase. AGM-290 underscores Anygen's effort to tackle the growing problem of antibiotic resistance.

• AGM-212

  Part of the pre-clinical development phase, AGM-212 targets the treatment of Type 2 Diabetes. This compound is a testament to Anygen's pursuit of innovative treatments for chronic conditions.

• AGM-217

  Also aimed at treating Type 2 diabetes and obesity, AGM-217 is under pre-clinical development. It is an illustration of Anygen's interdisciplinary approach to address both metabolic disorders simultaneously.

• AGM-260

  Indicated for the treatment of Ulcerative Colitis and currently under pre-clinical development, AGM-260 reflects Anygen's commitment to improving gastrointestinal health.